Trial · NCT06114537
The AXIS Study: the Efficacy of Acetazolamide for the Treatment of Cystoid Fluid Collections in Retinoschisis
NCT06114537, Phase 2, Completed, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The AXIS Study: the Efficacy of Acetazolamide for the Treatment of Cystoid Fluid Collections in Retinoschisis. Trials, record NCT06114537. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06114537
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The AXIS Study: the Efficacy of Acetazolamide for the Treatment of Cystoid Fluid Collections in Retinoschisis
- NCT number
- NCT06114537
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 19 participants, actual
- Lead sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Conditions
- Retinoschisis
- Interventions
- Acetazolamide
- First posted
- 2023-11-02
- Last updated
- 2025-05-31
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Macular structure as assessed by spectral domain optical coherence tomography | Change from baseline to Week 32 | Change in Central subfield thickness on spectral domain optical coherence tomography (SD-OCT). |
| Secondary | Visual acuity as assessed by low-luminance visual acuity | Change from baseline to Week 32 | Change in low luminance visual acuity (LLVA) |
| Secondary | Visual function as assessed by microperimetry | Change from baseline to Week 32 | Change in microperimetry. |
| Secondary | Subject-reported visual function as assessed by the Michigan Retinal Degeneration Questionnaire (MRDQ). | Change from baseline to Week 32 | Change in the functional (dis)ability score, theta score (θ), in the measured trait or domain. Θ is centred at the mean trait level of the patient population of the developers with a variance of 1, and extreme Θ-values -3 and + 3 indicate lowest and highest visual disability respectively of each patients. |
| Secondary | Absence of cystoid fluid collections on OCT scan | At evaluation visits during study (assessed up to 32 weeks) | Absence of cystoid fluid collections on OCT scan |
| Secondary | Visual acuity as assessed by best-corrected visual acuity | Change from baseline to Week 32 | Change in in best-corrected visual acuity (BCVA). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06114537
GET https://conductscience.org/api/trials/v1/NCT06114537/registered